Morgan Stanley named Omada Health (OMDA) as the firm’s Top Pick in Healthcare Technology with an Overweight rating and more than 100% upside to the firm’s $32 price target For healthcare technology and providers, the firm sees an “attractive backdrop for alpha-generation opportunities” in 2026, the analyst tells investors. For Omada, building investor confidence in margin expansion will be “key,” the analyst contends.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health’s Strategic Growth and Profitability: A Buy Rating by Craig Hettenbach
- Omada Health Positioned for Growth with Strong Financial Performance and Strategic Market Opportunities
- Omada Health initiated with an Outperform at BMO Capital
- Omada Health Reports Strong Growth and Innovation
- Omada Health price target raised to $32 from $30 at Morgan Stanley